Orthofix announces FDA approval of app for bone growth stimulators
Click Here to Manage Email Alerts
Orthofix announced an updated version of its bone growth stimulator app, STIM onTrack, was approved by the FDA.
According to a company press release, STIM onTrack, first introduced in 2017, accompanies Orthofix’s bone growth therapy devices. The company’s bone growth stimulators are an FDA-approved alternative to surgery for nonunion fractures and spinal healing that use pulsed electromagnetic fields to stimulate bone healing. STIM onTrack helps to regulate patients’ adherence to these stimulators.
The new version of the app, 2.1, has been updated to allow patients to virtually share their quality of life and functional well-being with their physician through patient-reported outcome measure questionnaires. Other app features include daily treatment reminders and a calendar that enables physicians to monitor their patients’ device usage.
“We are proud to be the first in the bone growth stimulation market to be able to deliver tools to support physician remote patient monitoring endeavors to aid in a joint vision of improving patient outcomes,” Kevin Kenny, president of Global Orthofix Spine, said in the release.
Reference:
www.orthofix.com